Compare TG Therapeutics Inc (TGTX) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Visa Inc — how do they compare? TG Therapeutics Inc trades at $55.24 (market cap $8.16B), while Visa Inc trades at $385.31 (market cap $704.20B). The key difference: Visa Inc is far larger — about 86.3× TG Therapeutics Inc's market cap, and Visa Inc pays a 0.71% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Visa Inc for 115 Days on average.
| TGTX | V | |
|---|---|---|
Market Cap | $8.16B | $704.20B |
Volume | 1,735,121 | 6,405,857 |
Sector | Health | Financials |
52-Week High | $59.06 | $384.14 |
52-Week Low | $26.94 | $295.52 |
Typical Hold Time | 16 Days | 115 Days |
Enterprise Value | $8.37B | $714.78B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Visa (V) trades at $383.79, up 3.14% today, showing strong momentum near its 52-week high. The stock maintains bullish technical signals with consistent earnings beats and robust fundamentals, including 50.78% net margins and 61.79% ROE. Recent developments include AI-powered commerce initiatives and stablecoin partnerships, positioning Visa at the forefront of payment innovation while maintaining dominant market positioning.
Visa presents a compelling investment case with strong analyst support (85% buy ratings) and a $422.24 price target offering 10% upside. However, elevated valuation multiples (P/E 31.92) and emerging fintech competition require monitoring. The company's consistent execution and AI integration provide growth catalysts, though regulatory scrutiny and payment disruption risks remain considerations for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
